An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
The MRI-based radiomics model could be used to noninvasively identify the AA response in mCRPC patients, which is helpful for early clinical decision-making.
Authors
- Shaoxian Chen
- Fang Fen
- Feng Shi (ORCID: https://orcid.org/0000-0003-1522-9943)
- Zehong Yang (ORCID: https://orcid.org/0000-0001-7562-3710)
- Yi Wu (ORCID: https://orcid.org/0009-0006-7758-9601)
- Yuwei Xia (ORCID: https://orcid.org/0000-0002-2248-2296)
- Daiying Lin (ORCID: https://orcid.org/0000-0002-7792-9753)
- Xiang Liu (ORCID: https://orcid.org/0000-0003-2682-3075)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- United Imaging Healthcare (China) (CN)
- Shantou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.3389/fonc.2025.1491848
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52